BACKGROUND
To date, studies investigating the association between stroke severity and previous use of aspirin have produced conflicting results.
OBJECTIVE
To assess in a large prospective data set whether stroke severity is linked to previous aspirin use.
DESIGN AND INTERVENTION
This was an analysis of 17,850 patients who participated in the International Stroke Trial (IST)-an open, randomized, controlled trial that investigated the efficacy of anti thrombotic therapy, started as soon as possible after onset of acute ischemic stroke. A total of 3,820 patients (21.4%) reported aspirin use in the 3 days before randomization to antithrombotic therapy or no therapy. The investigators evaluated the association between previous aspirin use and baseline stroke severity, with three methods being used to evaluate stroke severity: the Oxfordshire Community Stroke Project (OCSP) stroke classification system; the probability of death within 14 days, and of death or dependency at 6 months, predicted at baseline; and the observed outcome at 14 days and 6 months. The association between previous aspirin use and the following variables was also assessed: age, gender, presence of atrial fibrillation (AF), and presence of visible infarction on the baseline CT.
Is there a link between aspirin therapy and stroke severity?
OUTCOME MEASURE
The primary study endpoint was the asso ciation between previous aspirin use and baseline stroke severity.
RESULTS
Patients who reported previous aspirin use tended to be male (odds ratio [OR] 1.16, 95% CI 1.08-1.24), have AF (OR 1.11, 95% CI 1.01-1.22), be older (mean age 73 vs 71 years, P <0.0001) and have been randomized with a slightly greater delay following symptom onset (21 vs 20 h, P <0.0001) than patients who reported not to have used aspirin. After logistic regression analysis, gender, age and time to randomization remained significantly different between the groups (P <0.0001). There was no association between previous aspirin use and visible infarction on CT (OR 0.97, 95% CI 0.9-1.05). Previous aspirin use was not linked to the OCSP stroke subtype (P = 0.185); the result remained nonsignificant after adjustment for age, gender and AF (P = 0.67). Previous aspirin use also had no impact on the predicted probability of death within 14 days (P = 0.057) or on the predicted probability of a poor outcome at 6 months (P = 0.624). When limiting the analysis to the control group (n = 4,466, with 925 patients reporting previous aspirin use), there was, however, a significant association between previous aspirin use and the predicted probability of a poor outcome at 6 months (P = 0.004). The OR for a poor outcome at 6 months in control patients who reported previous use of aspirin was 1.31 (95% CI 1.13-1.53), but after adjustment for age, gender, AF and stroke type the result was no longer statistically significant (P = 0.073).
CONCLUSION
Aspirin use before an ischemic stroke had no effect on the baseline severity or the 6-month outcome of the subsequent stroke.
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Factors that modulate stroke severity and outcome are well described; for example, increased severity is associated with cortical (versus lacunar) stroke, and with cardio embolism or large-artery thrombosis (versus small-vessel disease). Similarly, a poor functional outcome is related to factors such as increasing age, more-severe stroke, high blood pressure 1 and the presence of AF. These factors appear to be independent of each other when analyzed using statistical techniques that allow adjustment for potential confounding factors. Many patients presenting with acute stroke have existing vascular disease and are on prophylactic drugs that are given with the aim of preventing further events. Inevitably, the question then arises as to whether these interventions not only reduce the risk of events, but also decrease their severity and improve outcome.
From a theoretical perspective, aspirin might reduce the severity of ischemic stroke, perhaps by reducing thrombus size or propagation, or because its use indicates treatment compliance and health-seeking behavior. Alternatively, this therapy might be associated with worse severity owing to confounding by indication (i.e. patients on aspirin are more likely to have comorbid conditions that themselves contribute to severity and a poor outcome). Previous studies have given conflicting results, indicating that patients taking aspirin before their ischemic stroke have either milder or more-severe stroke than patients who are not on aspirin. Ricci and co-workers assessed this question using data from 17,850 patients with ischemic stroke who were randomized into the first IST. 2 The authors assessed whether aspirin was associated with differences in stroke severity, judged in three different ways: by baseline clinical syndrome, predicted outcome (based on baseline clinical variables) and observed outcome. In some univariate analyses, prestroke aspirin usage was associated with increased stroke severity and a worse outcome. These associations became non significant, however, when adjusted for baseline prognostic factors including age, sex and AF. These results differ from earlier reports in that they are based on a prospective study with a far larger sample size. Furthermore, the results are likely to be representative of populations around the world, because the patients in the IST came from multiple centers in 20 countries. As the authors acknowledge, however, prestroke aspirin use was self-reported, data on length of aspirin usage and its dose were not available (so no dose-response curve could be generated), and the comparison of aspirin and non-aspirin usage was not randomized. Further, while the authors adjusted the analyses for some important covariates, they left out key prognostic factors such as diabetes and ischemic heart disease.
In conclusion, these data do not indicate that aspirin modulates subsequent stroke severity or functional outcome, contrary to earlier observations in smaller studies. This finding does not suggest, however, that aspirin is ineffective in protecting against stroke recurrence, and this drug must remain a key component of vascular prophylaxis. 3 When considering other vascular prophylactic strategies, statins also do not appear to alter the severity of subsequent strokes. 4 By contrast, a recent report concludes that the combination of antiplatelets, angiotensin-converting-enzyme inhibitors and statins might produce an additive reduction in stroke severity. 5 These studies were small, however, and, ultimately, only randomized controlled trials will resolve the important question of whether vascular prophylaxis has an impact on stroke severity. 
